Compare · AMGN vs MGX
AMGN vs MGX
Side-by-side comparison of Amgen Inc. (AMGN) and Metagenomi Therapeutics Inc. (MGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and MGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $186.05B, about 4152.9x MGX ($44.8M).
- Over the past year, AMGN is up 26.6% and MGX is down 15.8% - AMGN leads by 42.4 points.
- MGX has been more active in the news (7 items in the past 4 weeks vs 3 for AMGN).
- AMGN has more recent analyst coverage (25 ratings vs 8 for MGX).
- Company
- Amgen Inc.
- Metagenomi Therapeutics Inc.
- Price
- $344.75+2.16%
- $1.20-0.83%
- Market cap
- $186.05B
- $44.8M
- 1M return
- +3.98%
- -7.69%
- 1Y return
- +26.61%
- -15.79%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2024
- News (4w)
- 3
- 7
- Recent ratings
- 25
- 8
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)
Latest MGX
- SEC Form 4 filed by Director Reid Laurence
- SEC Form 4 filed by Director Dere Willard H
- SEC Form 4 filed by Director Bjerkholt Eric
- SEC Form 4 filed by Director Eckhardt Juergen
- Chief Financial Officer Wapnick Pamela sold $3,746 worth of shares (2,884 units at $1.30), decreasing direct ownership by 1% to 208,491 units (SEC Form 4) to satisfy withholding tax
- Officer Irish Jian sold $4,854 worth of shares (3,737 units at $1.30), decreasing direct ownership by 0.98% to 377,533 units (SEC Form 4) (for tax liability)
- Officer Wein Matthew sold $725 worth of shares (558 units at $1.30), decreasing direct ownership by 0.44% to 126,491 units (SEC Form 4) to satisfy withholding tax
- Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
- SEC Form 10-Q filed by Metagenomi Therapeutics Inc.
- Metagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits